GU CONNECT expert, Prof. Gert Attard provides a GU cancer update from ESMO 2020 for you.


GU cancer update by Prof. Gert Attard, University College London Cancer Institute, UK

 

Prof. Attard is a Cancer Research UK Clinician Scientist and Team Leader at The Institute of Cancer Research and an Honorary Medical Oncology Consultant at the Royal Marsden NHS Foundation Trust, London, UK. He graduated with a degree in Medicine from the University of Malta in June 1999 and obtained a PhD in Medicine from the University of London (ICR) in 2010. His main research interest is dissecting treatment resistance, currently with a focus on plasma DNA analysis, in order to inform on the development of novel therapeutics and biomarkers for castration-resistant prostate cancer (CRPC). He is an experienced clinical trialist in CRPC and a co-author of more than 100 peer-reviewed manuscripts, including several important papers on advanced prostate cancer. Prof. Attard’s many awards over the years include the ASCO Foundation Annual Merit Award in 2007, Prostate Cancer Foundation Young Investor Award in 2008, the AACR-GlaxoSmithKline Outstanding Clinical Scholar Award in 2009, the Medical Research Society/Academy of Medical Sciences Sue McCarthy Prize in 2010 and the McElwain award in 2010. Prof. Attard sits on a number of advisory boards and the editorial board of Annals of Oncology.

Prof. Gerhardt Attard has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Grants or contracts from Astellas Pharma, Blue Earth Therapeutics, Janssen, Veracye and Novartis

 

Consulting fees from Amgen, AstraZeneca, Astellas Pharma, Bayer, Blue Earth Therapeutics, Janssen-Cilag, Merck & Co, Merck Sorono Ltd, Novartis, Pfizer, Veracyte.

 

Payment or honoraria from Astellas Pharma, Janssen, Astrazeneca, Sanofi, Sandoz.

 

Support for attending meetings/travel from Amgen, Astellas Pharma, Bayer, Janssen, Merck Sorono Ltd, Pfizer

 

On the Institute of Cancer Research Discoveries list of abiraterone acetate. Listed as inventor on docetaxel predictive, biomarker (Veracyte).

 

Listed as inventor on patent related to blood biomarkers (UCL, Cancer Research Horizons)

 

Commercial agreements with employer, UCL with Artera and Veracyte

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

patient-support Patient Support
Oncology Endocrinology Rare diseases 
Navigating extrapulmonary neuroendocrine carcinoma (EP-NEC)

Insights for patients and care partners 

Experts
Meredith Cummins
Endorsed by
INCA
NeuroEndocrine Cancer Australia Neuroendocrine Cancer Foundation NET-Research-Foundation
Neuroendocrine Cancer UK Minkhas mission
  • clock 5 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim 
podcast Video podcast
Oncology Endocrinology Rare diseases 
Understanding EP-NEC: Through diagnosis, treatment, and support

A medical oncologist and a patient advocate share their perspectives

Experts
Dr Aman Chauhan, Susan Meckler-Plummer, RN
Endorsed by
Minkhas mission Neuroendocrine Cancer UK Neuroendocrine Cancer Foundation
NET-Research-Foundation
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Nov 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim 
conference-update Conference update
Oncology 
Update from AACR–NCI–EORTC 2025: PYNNACLE Phase 2 evaluating rezatapopt in TP53 Y220C–mutant solid tumours

Clinical insights and expert discussion

Experts
Dr Alison Schram, Dr Elena Garralda
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Oct 2025

This programme has been sponsored by PMV Pharma 
conference-update Conference update
Oncology 
Highlights from ESMO 2025

Experts join us at ESMO 2025 to share their views on new data on GU, lung, breast, gynecological and upper GI cancers

Experts
Dr Herbert Loong, Prof. Viktor Grünwald, Prof. Thomas Powles, Dr Elisa Agostinetto, Prof. Nicoletta Colombo, Dr Elizabeth Smyth
Endorsed by
Exon20group Biomarker Collaborative ICAN international cancer advocacy network
Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Oct 2025
  • Non-accredited Independent Medical Education

NSCLC and RCC updates supported by Independent Education Grants from Bayer and Eisai Europe Ltd. respectively. All other updates supported by COR2ED.